Cardiovascular Systems Inc (OQ:CSII)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 1225 Old Highway 8 NW
ST. PAUL MN 55112-6416
Tel: 1-651-2024919
IR: See website
Key People
Scott R. Ward
Chairman of the Board, President, Chief Executive Officer
Jeffrey S. Points
Chief Financial Officer
Rhonda J. Robb
Chief Operating Officer
Sandra Marie Sedo
Chief Compliance Officer
John M. Hastings
Vice President of Manufacturing and Operations
David S. Whitescarver
Vice President of Corporate Development and Intellectual Property
Alexander Rosenstein
General Counsel and Corporate Secretary
Ryan D. Egeland
Chief Medical Officer
Laura J. Gillund
Chief Talent Officer
Business Overview
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Financial Overview
For the three months ended 30 September 2019, Cardiovascular Systems Inc revenues increased 15% to $64.5M. Net loss increased 100% to $5.8M. Revenues reflect Peripheral Products segment increase of 10% to $45.5M, Coronary Products segment increase of 26% to $19M, United States segment increase of 12% to $61.5M, International segment increase from $1.3M to $3M. Higher net loss reflects Selling.
Employees: 731 as of Jun 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,760M as of Sep 30, 2019
Annual revenue (TTM): $256.24M as of Sep 30, 2019
EBITDA (TTM): -$0.22M as of Sep 30, 2019
Net annual income (TTM): -$3.15M as of Sep 30, 2019
Free cash flow (TTM): $2.01M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 35,199,895 as of Sep 30, 2019
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization